MCID: ALK016
MIFTS: 43

Alk-Negative Anaplastic Large Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Alk-Negative Anaplastic Large Cell Lymphoma:

Name: Alk-Negative Anaplastic Large Cell Lymphoma 58
Anaplastic Large Cell Lymphoma, Alk-Negative 17 32
Anaplastic Large Cell Lymphoma, Alk Negative 71
Anaplastic Large Cell Lymphoma, Alk-Positive 71
Alk- Anaplastic Large Cell Lymphoma 58
Alk- Alcl 58

Characteristics:

Orphanet epidemiological data:

58
alk-negative anaplastic large cell lymphoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 32 C84.7
ICD10 via Orphanet 33 C84.7
UMLS via Orphanet 72 C1332078
Orphanet 58 ORPHA300903
UMLS 71 C1332078 C1332079

Summaries for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards based summary : Alk-Negative Anaplastic Large Cell Lymphoma, also known as anaplastic large cell lymphoma, alk-negative, is related to alk-positive anaplastic large cell lymphoma and anaplastic large cell lymphoma. An important gene associated with Alk-Negative Anaplastic Large Cell Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Prednisone and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and breast, and related phenotypes are homeostasis/metabolism and growth/size/body region

Related Diseases for Alk-Negative Anaplastic Large Cell Lymphoma

Diseases in the Alk-Positive Anaplastic Large Cell Lymphoma family:

Alk-Negative Anaplastic Large Cell Lymphoma

Diseases related to Alk-Negative Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 117)
# Related Disease Score Top Affiliating Genes
1 alk-positive anaplastic large cell lymphoma 33.3 STAT3 ALK
2 anaplastic large cell lymphoma 31.1 STAT3 CXCR3 CCR4 ALK
3 lymphoma, hodgkin, classic 31.0 CCR4 BCL2L1 BCL2 ALK
4 reticulosarcoma 30.4 MYC BCL2 ALK
5 peripheral t-cell lymphoma 29.8 STAT3 DUSP22 CXCR3 CD274 CCR4 ALK
6 lymphoma 29.5 STAT3 MYC CD274 BCL2L1 BCL2 BAX
7 cutaneous t cell lymphoma 29.5 STAT3 CXCR3 CCR4 ADA
8 adult t-cell leukemia 29.3 PMAIP1 MYC CD274 CCR4 BCL2L1
9 t-cell leukemia 29.0 PMAIP1 MYC CD274 CCR4 BCL2L1 BAX
10 myeloma, multiple 28.5 STAT3 PMAIP1 MYC CD274 BCL2L1 ALK
11 lymphoma, non-hodgkin, familial 28.1 STAT3 PMAIP1 MYC DPP4 BCL2L1 BCL2
12 lymphomatoid papulosis 10.5
13 pleural lipoma 10.4 ALK ADA
14 indolent b-cell non-hodgkin lymphoma 10.4 BCL2L1 BAX
15 kashin-beck disease 10.4 BCL2 BAX
16 thrombocytopenia 10.4
17 primary mediastinal large b-cell lymphoma 10.3 CD274 BCL2
18 focal cortical dysplasia, type ii 10.2 BCL2L1 BCL2 BAX
19 diffuse large b-cell lymphoma of the central nervous system 10.2 MYC BCL2
20 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.2 MYC BCL2
21 immune deficiency disease 10.2
22 aplastic anemia 10.2
23 myelodysplastic syndrome 10.2
24 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.2
25 t-cell lymphoma, subcutaneous panniculitis-like 10.2
26 hemophagocytic lymphohistiocytosis 10.2
27 breast implant-associated anaplastic large cell lymphoma 10.2
28 lymphoblastic lymphoma 10.2
29 sarcoma 10.2
30 respiratory failure 10.2
31 disseminated intravascular coagulation 10.2
32 alcoholic hepatitis 10.2
33 hepatitis a 10.2
34 capillary leak syndrome 10.2
35 alcohol use disorder 10.2
36 ichthyosis 10.2
37 squamous cell carcinoma 10.2
38 spindle cell sarcoma 10.2
39 t-cell adult acute lymphocytic leukemia 10.2
40 neuropathy 10.2
41 hypereosinophilic syndrome 10.2
42 47,xyy 10.2
43 granulomatous slack skin disease 10.2
44 ichthyosis, acquired 10.2
45 soft tissue sarcoma 10.2
46 t-cell non-hodgkin lymphoma 10.2
47 rapidly involuting congenital hemangioma 10.2
48 primary cutaneous anaplastic large cell lymphoma 10.2
49 retinal ischemia 10.2 BCL2L1 BCL2 BAX
50 differentiated thyroid carcinoma 10.2 CD274 BCL2 ALK

Graphical network of the top 20 diseases related to Alk-Negative Anaplastic Large Cell Lymphoma:



Diseases related to Alk-Negative Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Alk-Negative Anaplastic Large Cell Lymphoma

MGI Mouse Phenotypes related to Alk-Negative Anaplastic Large Cell Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.15 ADA ALK BAX BCL2 BCL2L1 CD274
2 growth/size/body region MP:0005378 10.14 ADA ADARB1 ALK BAX BCL2 BCL2L1
3 endocrine/exocrine gland MP:0005379 10.09 ADA ALK BAX BCL2 BCL2L1 DPP4
4 mortality/aging MP:0010768 10.03 ADA ADARB1 ALK BAX BCL2 BCL2L1
5 immune system MP:0005387 10.02 ADA BAX BCL2 BCL2L1 CCR4 CD274
6 muscle MP:0005369 9.76 ADA ADARB1 BAX BCL2 MSC MYC
7 neoplasm MP:0002006 9.61 ALK BAX BCL2 BCL2L1 CXCR3 FRK
8 respiratory system MP:0005388 9.17 ADA ALK BAX CCR4 CXCR3 STAT3

Drugs & Therapeutics for Alk-Negative Anaplastic Large Cell Lymphoma

Drugs for Alk-Negative Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
3
Pirarubicin Investigational Phase 4 72496-41-4
4 Antimitotic Agents Phase 4
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
7 Alkylating Agents Phase 3
8 Topoisomerase Inhibitors Phase 3
9 Antirheumatic Agents Phase 3
10 Immunosuppressive Agents Phase 3
11 Immunologic Factors Phase 3
12 Hormone Antagonists Phase 3
13 Anti-Inflammatory Agents Phase 3
14 Antineoplastic Agents, Hormonal Phase 3
15 glucocorticoids Phase 3
16 Hormones Phase 3
17 Anti-Bacterial Agents Phase 3
18 Antibiotics, Antitubercular Phase 3
19
Liposomal doxorubicin Phase 3 31703
20
Carmustine Approved, Investigational Phase 1, Phase 2 154-93-8 2578
21
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
22
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
23
alemtuzumab Approved, Investigational Phase 2 216503-57-0
24
nivolumab Approved Phase 2 946414-94-4
25
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
26
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
27
Etoposide Approved Phase 2 33419-42-0 36462
28
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
29
leucovorin Approved Phase 2 58-05-9 6006 143
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
31
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
32
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
33
Ifosfamide Approved Phase 2 3778-73-2 3690
34
Ichthammol Approved Phase 2 8029-68-3
35
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
36
Phenylalanine Approved, Investigational, Nutraceutical Phase 1, Phase 2 63-91-2 6140
37
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
38
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
39
Cortisone Experimental Phase 1, Phase 2 53-06-5 222786
40
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
41 Nitrogen Mustard Compounds Phase 1, Phase 2
42 Tin Fluorides Phase 2
43 Angiogenesis Inhibitors Phase 1, Phase 2
44 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
45 Podophyllotoxin Phase 2 518-28-5
46 Anti-Infective Agents Phase 2
47 Antiviral Agents Phase 2
48 Antimetabolites Phase 2
49 Etoposide phosphate Phase 2
50 Folic Acid Antagonists Phase 2

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
2 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
3 Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma Completed NCT01035463 Phase 1, Phase 2 Carmustine;Cytarabine;Etoposide;Lenalidomide;Melphalan
4 A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;Vincristine;pralatrexate
5 Intensive Chemo-immunotherapy as First-line Treatment in Adult Patients With Peripheral T-cell Lymphoma (PTCL) Completed NCT01679860 Phase 2 Clin B (CHOP- CAMPATH) Chemo-immunotherapy
6 A Phase II Study of Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma Recruiting NCT03719898 Phase 2 Brigatinib
7 Phase II Trial of Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) Recruiting NCT03703050 Phase 2 Nivolumab cohort 1;Nivolumab cohort 2
8 A Phase 2 Open Label Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma Previously Treated With ALK Inhibitors (CRU3) Recruiting NCT03505554 Phase 2 Lorlatinib
9 Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas Recruiting NCT02419287 Phase 2 crizotinib
10 A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma Active, not recruiting NCT02561273 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
11 A "Window of Opportunity" Trial With Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma or Patients Ineligible for Chemotherapy Active, not recruiting NCT02462538 Phase 1, Phase 2 Brentuximab vedotin;Imatinib
12 Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL Active, not recruiting NCT02572453 Phase 2 Onalespib
13 A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL) Suspended NCT01979536 Phase 2 Brentuximab Vedotin;Crizotinib;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Methotrexate
14 A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma Withdrawn NCT02729961 Phase 1, Phase 2 Brentuximab Vedotin;Ceritinib
15 A Phase 1 Study of Interleukin-15 in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies. Recruiting NCT03905135 Phase 1 rhIL-15
16 Expression of T Immunoregulatory Proteins in ALK+ Anaplastic Large Cell Lymphoma (ALCL) Completed NCT01366170
17 Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma Recruiting NCT03603847

Search NIH Clinical Center for Alk-Negative Anaplastic Large Cell Lymphoma

Genetic Tests for Alk-Negative Anaplastic Large Cell Lymphoma

Anatomical Context for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Alk-Negative Anaplastic Large Cell Lymphoma:

40
T Cells, B Cells, Breast, Myeloid, Bone, Bone Marrow, Lung

Publications for Alk-Negative Anaplastic Large Cell Lymphoma

Articles related to Alk-Negative Anaplastic Large Cell Lymphoma:

(show top 50) (show all 123)
# Title Authors PMID Year
1
ALK-negative anaplastic large cell lymphoma with "Hodgkin-like" cytomorphology and nuclear expression of PAX5. 61
31784094 2020
2
Leukemic phase of ALK-negative anaplastic large cell lymphoma in a patient who is on androgenic steroids: A case report. 61
31871676 2020
3
Endobronchial Pseudocarcinomatous Hyperplasia Mimicking Squamous Cell Carcinoma Associated with Primary Pulmonary ALK-negative Anaplastic Large Cell Lymphoma. 61
31705818 2019
4
[Detection of chromosomal translocations of DUSP22 and TP63 in ALK-negative anaplastic large cell lymphoma by fluorescence in situ hybridization and related clinical relevance]. 61
31594044 2019
5
DUSP22-IRF4 rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma. 61
31570354 2019
6
Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. 61
30873584 2019
7
Pediatric mediastinal ALK- negative anaplastic large cell lymphoma (Hodgkin-like pattern) in a 13-year-old girl: a case report and review of literature. 61
31772744 2019
8
Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms. 61
31278738 2019
9
Primary ALK-negative anaplastic large cell lymphoma with extensive bone involvement mimicking multiple myeloma and metastatic carcinoma. 61
31093934 2019
10
Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma. 61
31101622 2019
11
ALK-negative anaplastic large cell lymphoma arising in the thrombus of an aortic prosthesis preceeded by clonally related lymphomatoid papulosis. 61
30685783 2019
12
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. 61
30829413 2019
13
A Rare Case of Neutrophil-Rich, ALK-Negative Anaplastic Large Cell Lymphoma in the Lung Mimicking a Pulmonary Abscess on 18F-FDG PET/CT. 61
30562196 2019
14
Acquired ichthyosis as a paraneoplastic feature of ALK-negative anaplastic large cell lymphoma. 61
30407628 2019
15
[Clinicopathological characteristics of adult T cell leukemia/lymphoma]. 61
30641639 2019
16
Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type. 61
30151671 2018
17
FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the spectrum of T-cell lymphomas with regulatory phenotype. 61
29898383 2018
18
Adult T-cell leukemia/lymphoma can be indistinguishable from other more common T-cell lymphomas. The University of Miami experience with a large cohort of cases. 61
29449683 2018
19
The Long Non-Coding RNA MIR503HG Enhances Proliferation of Human ALK-Negative Anaplastic Large-Cell Lymphoma. 61
29758012 2018
20
Prognostic factors of ALK-negative anaplastic large-cell lymphoma: a single-institution experience. 61
29359238 2018
21
Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. 61
29026208 2018
22
ALK-Negative Anaplastic Large Cell Lymphoma Presenting as Disseminated Intravascular Coagulation and Hemophagocytic Lymphohistiocytosis: A Potentially Fatal Presentation. 61
29850298 2018
23
Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma. 61
28370436 2017
24
ALK-Negative Anaplastic Large Cell Lymphoma Presenting as an Extranodal Soft-Tissue Mass With an Unusual Alveolar Growth Pattern: A Diagnostic Challenge. 61
28381153 2017
25
Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma. 61
29100307 2017
26
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. 61
28344319 2017
27
DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. 61
28522440 2017
28
Indolent ALK-negative anaplastic large-cell lymphoma, DUSP22 rearranged, with an unusual immunophenotype in a human immunodeficiency virus patient. 61
28042680 2017
29
PAX-5 Positivity in Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma: A Case Report and Review of Literature. 61
28013563 2017
30
Primary Soft Tissue Lymphomas: Description of Seven Cases and Review of the Literature. 61
27480544 2017
31
ALK-negative anaplastic large cell lymphoma with urinary bladder involvement diagnosed in urine cytology: A case report and literature review. 61
28139895 2017
32
[Primary ALK-negative anaplastic large cell lymphoma of breast: report of a case]. 61
28072980 2017
33
Anaplastic large cell lymphoma masquerading as osteomyelitis of the shoulder: an uncommon presentation. 61
28003232 2016
34
[Granulomatous slack skin associated with ALK-negative anaplastic large cell lymphoma]. 61
28056306 2016
35
Cyclin D1 expression in peripheral T-cell lymphomas. 61
27469326 2016
36
[Comparison of allogeneic or autologous hematopoietic stem cell transplant for high-risk peripheral T cell lymphomas]. 61
27995879 2016
37
ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. 61
27460479 2016
38
[Outcome of haploidentical hematopoietic stem cell transplantation for non-Hodgkin lymphoma]. 61
27587245 2016
39
Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience. 61
27209536 2016
40
Cytological Diagnosis of Bilateral Breast Implant-Associated Lymphoma of the ALK-Negative Anaplastic Large-Cell Type. Clinical Implications of Peri-Implant Breast Seroma Cytological Reporting. 61
27079579 2016
41
ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin. 61
27263791 2016
42
A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. 61
26861608 2016
43
Upregulated Neuro-oncological Ventral Antigen 1 (NOVA1) Expression Is Specific to Mature and Immature T- and NK-Cell Lymphomas. 61
26922803 2016
44
Overexpression of TMOD1 is associated with enhanced regional lymph node metastasis in human oral cancer. 61
26718916 2016
45
Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. 61
26598546 2016
46
ALK-negative anaplastic large-cell lymphoma. 61
26769771 2016
47
Primary gastric anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma. 61
27695344 2016
48
Successful Cord Blood Stem Cell Transplantation for an Adult Case of Chronic Active Epstein-Barr Virus Infection. 61
27904117 2016
49
Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin. 61
26809026 2016
50
Primary CNS T-cell Lymphomas: A Clinical, Morphologic, Immunophenotypic, and Molecular Analysis. 61
26379152 2015

Variations for Alk-Negative Anaplastic Large Cell Lymphoma

Expression for Alk-Negative Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Alk-Negative Anaplastic Large Cell Lymphoma.

Pathways for Alk-Negative Anaplastic Large Cell Lymphoma

Pathways related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.79 STAT3 PMAIP1 MYC CXCR3 CCR4 BCL2L1
2
Show member pathways
13.64 STAT3 MYC CXCR3 CCR4 BCL2L1 BCL2
3
Show member pathways
12.89 STAT3 MYC CCR4 BCL2L1 BCL2 BAX
4
Show member pathways
12.82 STAT3 PMAIP1 MYC BCL2L1 BCL2 BAX
5
Show member pathways
12.78 STAT3 MYC BCL2L1 BCL2 BAX
6
Show member pathways
12.72 TP63 PMAIP1 MYC BCL2L1 BCL2 BAX
7 12.59 STAT3 PMAIP1 MYC BCL2L1 BCL2 BAX
8
Show member pathways
12.58 STAT3 MYC BCL2L1 BCL2 BAX
9
Show member pathways
12.55 STAT3 MYC BCL2L1 BCL2
10
Show member pathways
12.55 STAT3 MYC BCL2L1 BCL2 BAX
11
Show member pathways
12.52 STAT3 BCL2L1 BCL2 BAX
12 12.49 TP63 STAT3 MYC BCL2
13
Show member pathways
12.43 STAT3 MYC BCL2L1 BCL2 BAX
14
Show member pathways
12.36 STAT3 MYC BCL2L1 BAX
15
Show member pathways
12.32 STAT3 MYC BCL2L1 BCL2
16 12.27 STAT3 PMAIP1 CCR4 BAX
17
Show member pathways
12.26 PMAIP1 MYC BCL2L1 BCL2 BAX
18
Show member pathways
12.18 MYC BCL2L1 BCL2 BAX
19 12.17 STAT3 MYC BCL2L1 BAX
20 12.03 PMAIP1 MYC BCL2L1 BCL2 BAX
21 12.02 TP63 PMAIP1 BCL2 BAX
22
Show member pathways
11.94 BCL2L1 BCL2 BAX
23 11.93 PMAIP1 MYC BCL2 BAX
24 11.92 STAT3 MYC BCL2L1 BCL2
25
Show member pathways
11.9 TP63 PMAIP1 BAX
26 11.87 STAT3 BCL2 BAX
27
Show member pathways
11.81 STAT3 MYC BCL2L1 BCL2
28
Show member pathways
11.8 STAT3 MYC BCL2L1
29 11.77 PMAIP1 MYC BAX
30 11.75 MYC BCL2 ADA
31 11.74 MYC BCL2L1 BCL2 BAX
32
Show member pathways
11.68 PMAIP1 BCL2L1 BCL2 BAX
33
Show member pathways
11.67 MYC BCL2L1 BCL2
34
Show member pathways
11.65 TP63 PMAIP1 BCL2L1 BCL2 BAX
35 11.6 PMAIP1 BCL2L1 BCL2 BAX
36 11.54 BCL2L1 BCL2 BAX
37 11.54 STAT3 MYC BCL2L1
38 11.48 MYC BCL2 BAX
39
Show member pathways
11.48 STAT3 MYC BCL2L1
40 11.45 MYC BCL2 BAX
41 11.36 PMAIP1 BCL2L1 BAX
42 11.33 STAT3 MYC BCL2L1
43 11.27 BCL2L1 BCL2 BAX
44
Show member pathways
11.26 PMAIP1 BCL2L1 BCL2 BAX
45
Show member pathways
11.2 STAT3 MYC BCL2L1 BCL2
46 11.17 MYC BCL2 BAX
47 11.05 BCL2L1 BCL2 BAX
48 10.99 BCL2 BAX
49 10.68 BCL2 BAX

GO Terms for Alk-Negative Anaplastic Large Cell Lymphoma

Cellular components related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.8 TP63 STAT3 PMAIP1 MYC BCL2L1 BCL2
2 pore complex GO:0046930 9.16 BCL2 BAX
3 Bcl-2 family protein complex GO:0097136 8.96 BCL2L1 BAX
4 mitochondrial outer membrane GO:0005741 8.92 PMAIP1 BCL2L1 BCL2 BAX

Biological processes related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10.1 TP63 STAT3 MYC MSC FRK DUSP22
2 apoptotic process GO:0006915 10.06 TP63 PMAIP1 CXCR3 BCL2L1 BCL2 BAX
3 negative regulation of apoptotic process GO:0043066 10.04 STAT3 MYC BCL2L1 BCL2 ADA
4 positive regulation of cell proliferation GO:0008284 10.04 STAT3 MYC DPP4 BCL2L1 BCL2
5 negative regulation of cell proliferation GO:0008285 10.02 STAT3 FRK BCL2 BAX ADARB1
6 response to drug GO:0042493 9.96 STAT3 MYC BCL2 ADA
7 cytokine-mediated signaling pathway GO:0019221 9.96 STAT3 MYC BCL2L1 BCL2
8 regulation of cell proliferation GO:0042127 9.92 STAT3 FRK DUSP22 ALK
9 regulation of cell cycle GO:0051726 9.88 STAT3 BCL2 BAX ADARB1
10 regulation of apoptotic process GO:0042981 9.85 TP63 PMAIP1 BCL2L1 BCL2 BAX ALK
11 male gonad development GO:0008584 9.84 BCL2L1 BCL2 BAX
12 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.77 BCL2L1 BCL2 BAX
13 ovarian follicle development GO:0001541 9.74 BCL2L1 BCL2 BAX
14 response to radiation GO:0009314 9.72 CCR4 BCL2L1 BCL2
15 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.71 BCL2L1 BCL2 BAX
16 response to cytokine GO:0034097 9.71 STAT3 CD274 BCL2L1 BCL2
17 regulation of mitochondrial membrane potential GO:0051881 9.7 BCL2L1 BCL2 BAX
18 response to gamma radiation GO:0010332 9.69 MYC BCL2 BAX
19 endoplasmic reticulum calcium ion homeostasis GO:0032469 9.67 BCL2 BAX
20 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.67 TP63 PMAIP1 BCL2
21 negative regulation of mitochondrial membrane potential GO:0010917 9.65 PMAIP1 BAX
22 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.65 TP63 BAX
23 positive regulation of protein oligomerization GO:0032461 9.64 PMAIP1 BAX
24 regulation of protein heterodimerization activity GO:0043497 9.63 BCL2 BAX
25 cell proliferation GO:0008283 9.63 TP63 STAT3 BCL2L1 BCL2 BAX ALK
26 neuron apoptotic process GO:0051402 9.62 TP63 BCL2L1 BCL2 BAX
27 protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:0001844 9.61 PMAIP1 BAX
28 leukocyte homeostasis GO:0001776 9.61 BCL2 BAX
29 apoptotic mitochondrial changes GO:0008637 9.61 BCL2L1 BCL2 BAX
30 regulation of protein homodimerization activity GO:0043496 9.59 BCL2 BAX
31 regulation of cell-cell adhesion mediated by integrin GO:0033632 9.56 DPP4 ADA
32 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.56 PMAIP1 BCL2L1 BCL2 BAX
33 positive regulation of developmental pigmentation GO:0048087 9.48 BCL2 BAX
34 regulation of nitrogen utilization GO:0006808 9.46 BCL2 BAX
35 release of cytochrome c from mitochondria GO:0001836 9.26 PMAIP1 BCL2L1 BCL2 BAX
36 regulation of mitochondrial membrane permeability GO:0046902 8.92 STAT3 PMAIP1 BCL2L1 BCL2

Molecular functions related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.56 TP63 STAT3 DPP4 CXCR3 BCL2L1 BCL2
2 adenosine deaminase activity GO:0004000 9.16 ADARB1 ADA
3 BH3 domain binding GO:0051434 8.8 BCL2L1 BCL2 BAX

Sources for Alk-Negative Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....